Get the Stockscreener App
13.10
0.23%
0.03
Amylyx Pharmaceuticals Inc stock is traded at $13.10, with a volume of 785.58K.
It is up +0.23% in the last 24 hours and up +6.24% over the past month.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
See More
Previous Close:
$13.07
Open:
$13.15
24h Volume:
785.58K
Relative Volume:
0.48
Market Cap:
$1.44B
Revenue:
$-249.00K
Net Income/Loss:
$-187.60M
P/E Ratio:
-5.24
EPS:
-2.5
Net Cash Flow:
$-201.88M
1W Performance:
-7.75%
1M Performance:
+6.24%
6M Performance:
+137.32%
1Y Performance:
+197.05%
1-Day Range:
$12.92
$13.44
1-Week Range:
$12.69
$14.76
52-Week Range:
$2.865
$16.96
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Name
Amylyx Pharmaceuticals Inc
Sector
Industry
Phone
617-683-0917
Address
43 THORNDIKE STREET, CAMBRIDGE
Compare AMLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
13.10 | 1.44B | -249.00K | -187.60M | -201.88M | -2.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Guggenheim | Buy |
| Jun-17-25 | Initiated | Citigroup | Buy |
| May-30-25 | Initiated | TD Cowen | Buy |
| Apr-07-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-18-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-23-24 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-18-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-11-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-11-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-08-24 | Downgrade | Goldman | Buy → Neutral |
| Jan-03-24 | Initiated | Robert W. Baird | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Jul-24-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Jan-05-23 | Initiated | BofA Securities | Buy |
| May-25-22 | Initiated | Citigroup | Buy |
| Apr-01-22 | Downgrade | Goldman | Buy → Neutral |
View All
Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News
TFG Asset Management GP Ltd Makes New $1.40 Million Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
683 Capital Management LLC Has $13.85 Million Stake in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
ALS medication AMX0114 shows safety, moves to 2nd trial group - ALS News Today
Amylyx pins its next hopes on a niche drug in the obesity space - Pharma Voice
Is Early AMX0114 Safety Data Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)? - Yahoo Finance
Is Amylyx Pharmaceuticals (AMLX) Overvalued After Its 250% Year‑to‑Date Share Price Surge? - Sahm
Amylyx presents safety outcomes of AMX0114 in LUMINA study - MSN
Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? - Nasdaq
Amylyx Pharmaceuticals Inc (AMLX) Receives a Buy from Mizuho Securities - The Globe and Mail
Amylyx’s ALS drug AMX0114 shows positive early safety data By Investing.com - Investing.com Nigeria
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Positive Buy Rating for Amylyx Pharmaceuticals Based on Promising Phase I LUMINA Study Results and Strategic Advancements - TipRanks
Presentation at MNDA: Characterizing the CSF Biomarker Signature of Calpain-2 Activity in ALS and Its Application in the Phase 1 LUMINA Trial (dae63b) - marketscreener.com
Amylyx’s ALS drug AMX0114 shows positive early safety data - Investing.com India
Amylyx Pharmaceuticals announces new safety and tolerability cohort 1 data of amx0114 - marketscreener.com
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial - Business Wire
Amylyx Pharmaceuticals, Inc. $AMLX Stock Position Increased by Saturn V Capital Management LP - MarketBeat
Amylyx Pharmaceuticals, Inc. $AMLX Stock Position Lifted by Alpha Wave Global LP - MarketBeat
Can Amylyx Pharmaceuticals Inc. stock sustain revenue growthJuly 2025 Spike Watch & Long-Term Safe Return Strategies - Newser
Camille Bedrosian Sells 6,580 Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock - MarketBeat
Geode Capital Management LLC Acquires 886,252 Shares of Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Top Executive Makes Significant Stock Sale at Amylyx Pharmaceuticals - TipRanks
Transcript : Amylyx Pharmaceuticals, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 04 - marketscreener.com
Amylyx Pharmaceuticals CMO Sells Shares to Cover Tax Obligations - TradingView
Officer Bedrosian Surrenders 6,580 Of Amylyx Pharmaceuticals Inc [AMLX] - TradingView
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? - Yahoo Finance
Key facts: Amylyx nears phase III trial for Avexitide; Bedrosian to sell shares - TradingView
Officer Bedrosian Files To Sell 6,580 Of Amylyx Pharmaceuticals Inc [AMLX] - TradingView
Amylyx Pharmaceuticals' co-CEO Justin Klee sells $41,103 in shares - MSN
RSI Check: Will Amylyx Pharmaceuticals Inc. stock benefit from sector rotationJuly 2025 Patterns & High Conviction Investment Ideas - moha.gov.vn
HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - marketscreener.com
How Amylyx Pharmaceuticals Inc. stock trades before earningsPortfolio Update Summary & Low Risk Growth Stock Ideas - moha.gov.vn
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead - AOL.com
Kennondale Capital Management LLC Has $610,000 Stake in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
17,551 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Acquired by ProShare Advisors LLC - MarketBeat
Amylyx Pharmaceuticals Reports Strong Q3 2025 Results - MSN
Amylyx Pharmaceuticals Inc. (AMLX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
How sustainable is Amylyx Pharmaceuticals Inc. stock dividend payoutWeekly Trade Analysis & Free Expert Approved Momentum Trade Ideas - newser.com
Is Amylyx Pharmaceuticals Inc. stock positioned for digital transformationWeekly Stock Recap & Consistent Growth Stock Picks - newser.com
Can Amylyx Pharmaceuticals Inc. stock reach $100 price targetJuly 2025 Volume & Real-Time Stock Price Movement Reports - newser.com
Is Amylyx Pharmaceuticals Inc. stock attractive for growth ETFsOil Prices & Weekly Watchlist for Consistent Profits - newser.com
What the charts say about Amylyx Pharmaceuticals Inc. today2025 Year in Review & Stepwise Trade Signal Guides - newser.com
Will Amylyx Pharmaceuticals Inc. stock deliver better than expected guidanceGap Up & Weekly Return Optimization Plans - newser.com
Real time social sentiment graph for Amylyx Pharmaceuticals Inc.2025 Pullback Review & Verified Momentum Watchlists - newser.com
Amylyx Pharmaceuticals Inc Stock (AMLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):